Trisalus Life Sciences, Inc. — Form 8-K Summary
Filing date: March 11, 2024. The filing reports preliminary unaudited financial information for the fiscal quarter and year ended December 31, 2023. Results were not yet finalized, and the independent registered public accounting firm had not audited, reviewed, compiled, or performed agreed-upon procedures on the data.
Financial Metrics
- Fourth-quarter 2023 revenue: Approximately $5.7 million, generated solely by the TriNav Infusion System.
- Fourth-quarter revenue growth: Approximately 77% compared with the fourth quarter of 2022.
- Full-year 2023 revenue: Approximately $18.5 million.
- Full-year revenue growth: Approximately 49% compared with 2022.
- Gross margin: Approximately 90% in the fourth quarter and 86% for full-year 2023, compared with 75% and 82%, respectively, in the comparable 2022 periods.
- Cash and cash equivalents: Approximately $11.8 million as of December 31, 2023.
- Liquidity: Management expected existing liquidity to fund operations into the second quarter of 2024.
- Profit, cash flow, and debt: The filing does not provide clear preliminary values for net income, operating cash flow, free cash flow, or debt.
Material Changes and Unusual Items
- Revenue increased substantially year over year in both the fourth quarter and full year, with revenue driven solely by the TriNav Infusion System.
- Gross margin improved by approximately 15 percentage points in the fourth quarter and 4 percentage points for the full year versus the respective 2022 periods.
- The disclosed figures remain estimates and may change because of financial closing procedures and final adjustments.
Outlook, Risks, and Contingencies
The company projected sufficient liquidity to fund operations into the second quarter of 2024 but specifically identified the need to obtain additional liquidity and the ability to continue as a going concern as risks. Other risks include results differing from preliminary estimates, failure to sustain revenue growth or current revenue levels, competition, rapid industry changes, and risks described in the company’s other SEC filings.
The filing does not provide formal revenue or profitability guidance beyond the preliminary 2023 estimates and liquidity projection. The company stated that forward-looking statements should not be relied upon as predictions of future events and undertook no obligation to update them except as required by law.
Investor Verification Items
- Verify the final audited 2023 financial statements and any changes from the preliminary revenue, gross margin, and cash estimates.
- Review net loss, operating cash flow, cash burn, working capital, debt, and going-concern disclosures when the full results are filed.
- Assess whether the company obtained additional financing before or during the second quarter of 2024.
- Evaluate the sustainability of revenue growth and gross-margin expansion given the concentration of reported revenue in the TriNav Infusion System.
- Review the company’s subsequent SEC filings and risk-factor disclosures for developments affecting liquidity and operations.